SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
June 22 2021 - 9:05AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the
“Company”), a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapies for a broad range of
indications, today announced that the Company will be included in
the Russell Microcap® Index effective after the U.S. market opens
on Monday, June 28, 2021, as based on the preliminary list of
additions. Russell indexes are widely used by investment managers
and institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in
assets are benchmarked against Russell's US indexes. Russell
indexes are part of FTSE Russell, a leading global index
provider.“Inclusion in the Russell Microcap® Index represents
another important milestone for SELLAS and is an achievement that
will undoubtedly increase awareness and visibility of our company
within the investment community,” said Angelos Stergiou, MD, ScD
hc, President and Chief Executive Officer, SELLAS. “Our inclusion
is a testament to our diligent work on our clinical development
programs for our lead asset, galinpepimut-S (GPS) which have the
potential to result in a treatment for multiple cancer indications
that will help patients to stay in remission and live longer. We
look forward to sharing the SELLAS story as well as updates on our
execution and milestones, which are currently on track, with a
wider investor audience as part of the FTSE Russell Microcap®
Index.”
Membership in the Russell Microcap® Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective
market-capitalization rankings and style attributes.
For more information on the Russell
Microcap® Index and the Russell indexes reconstitution, go to
the "Russell Reconstitution" section on the FTSE Russell
website.
About FTSE Russell:FTSE Russell is
a global index leader that provides innovative benchmarking,
analytics and data solutions for investors worldwide. FTSE Russell
calculates thousands of indexes that measure and benchmark markets
and asset classes in more than 70 countries, covering 98% of the
investable market globally.
FTSE Russell index expertise and products are used
extensively by institutional and retail investors globally.
Approximately $17.9 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based
derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly owned by London Stock
Exchange Group. About SELLAS Life Sciences Group,
Inc.SELLAS is a late-stage clinical biopharmaceutical
company focused on developing novel cancer immunotherapeutics for a
broad range of indications. SELLAS’ lead product candidate, GPS, is
licensed from Memorial Sloan Kettering Cancer Center and targets
the WT1 protein, which is present in an array of tumor types. GPS
has potential both as a monotherapy and in combination to address a
broad spectrum of hematologic malignancies and solid tumor
indications. SELLAS’ second product candidate, nelipepimut-S (NPS),
is a HER2-directed cancer immunotherapy with potential to treat
patients with early-stage breast cancer with low to intermediate
HER2 expression, otherwise known as HER2 1+ or 2+, which includes
triple negative breast cancer patients, following the standard of
care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Forward-Looking StatementsThis
press release contains forward-looking statements. All statements
other than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, forward-looking statements can be identified by terminology
such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,”
“should,” “project,” “believe,” “estimate,” “predict,” “potential,”
“intend,” or “continue” and other words or terms of similar
meaning. These statements include, without limitation, statements
related to the inclusion in the Russell Microcap Index.. These
forward-looking statements are based on current plans, objectives,
estimates, expectations and intentions, and inherently involve
significant risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with the COVID-19 pandemic and its impact
on the Company’s clinical plans, risks and uncertainties associated
with immune-oncology product development and clinical success
thereof, the uncertainty of regulatory approval, and other risks
and uncertainties affecting SELLAS and its development programs as
set forth under the caption “Risk Factors” in SELLAS’ Annual Report
on Form 10-K filed on March 23, 2021 and in its other SEC filings.
Other risks and uncertainties of which SELLAS is not currently
aware may also affect SELLAS’ forward-looking statements and may
cause actual results and the timing of events to differ materially
from those anticipated. The forward-looking statements herein are
made only as of the date hereof. SELLAS undertakes no obligation to
update or supplement any forward-looking statements to reflect
actual results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
For more information, please
contact:
Investor ContactsValter Pinto /
Allison SossKCSA Strategic
CommunicationsEmail: SELLAS@kcsa.comPhone: 914.907.2675 /
215.272.2707
Media ContactsCaitlin Kasunich /
Raquel ConaKCSA Strategic
CommunicationsEmail: SELLAS@kcsa.comPhone: 212.896.1241 /
212.896.1276
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024